Manejo de perfiles de pacientes con diabetes mellitus tipo 2 en la práctica clínica de la atención primaria en España: Programa CONTROVERTI2

Rebollar, Juan Carlos Obaya; Jiménez, Sara; Osoro, I. Aranbarri; Barrera, Francisco; Soidán, Francisco Javier García; Cebrián-Cuenca, Ana M

doi:10.1016/j.semerg.2021.07.009

Cited by 3 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent survey on the use of glucose-lowering medication in primary care in Spain (CONTROVERTI2) showed that the use of GLP-1 RAs is associated with patients with T2D and obesity, while patients with established CVD are preferentially treated with SGLT2 inhibitors [ 33 ]. However, a national level study of elderly patients with T2D admitted to hospital and at very high CV risk concluded that most were not being treated with these drugs [ 34 ].…”

Section: How Are Glp-1 Ras Being Used In Spain?mentioning

confidence: 99%

“…Currently, the focus of diabetes treatment has shifted from strict glycaemic control to a more comprehensive approach that considers prevention or control of CVD, kidney disease or other diabetes complications [ 13 , 42 ]. Accordingly, a recent survey suggested that one of the most influential clinical factors in the choice of glucose-lowering treatment in Spain is the presence of CVD (the other being high HbA1c) [ 33 ]. The current guidelines recommend SGLT2 inhibitors or GLP-1 RAs for the management of patients with T2D and established atherosclerotic CVD, while SGLT2 inhibitors are preferred for patients at risk of heart failure [ 2 ].…”

Section: Potential Reasons That Limit the Use Of Glp-1 Ras Based On T...mentioning

confidence: 99%

See 1 more Smart Citation

GLP-1 RAs in Spain: A Short Narrative Review of Their Use in Real Clinical Practice

et al. 2023

View full text Add to dashboard Cite

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are a class of drugs with potent glucoselowering activity. Additionally, some GLP-1 RAs have demonstrated cardiovascular and renal benefits. Current guidelines recommend their use in patients with type 2 diabetes (T2D) at high risk of or with established cardiovascular disease (CVD), regardless of glycaemic control, with lifestyle modification and metformin. However, several studies have recently highlighted the limited number of patients with T2D benefiting from these medications worldwide. Given the huge burden of CVD among patients with T2D, efforts should be made to bring clinical practice closer to expert guidelines. This review describes the current situation of GLP-1 RA use in Spain and the reasons behind the gap between guidelines and realworld practice and suggests possible solutions.

show abstract

Section: How Are Glp-1 Ras Being Used In Spain?mentioning

confidence: 99%

Section: Potential Reasons That Limit the Use Of Glp-1 Ras Based On T...mentioning

confidence: 99%

GLP-1 RAs in Spain: A Short Narrative Review of Their Use in Real Clinical Practice

et al. 2023

View full text Add to dashboard Cite

show abstract

Barriers and Strategies to Optimize the Use of Glucagon-Like Peptide 1 Receptor Agonists in People with Type 2 Diabetes and High Cardiovascular Risk or Established Cardiovascular Disease: A Delphi Consensus in Spain

Botana López,

Camafort Babkowski,

Campuzano Ruiz

et al. 2024

Adv Ther

View full text Add to dashboard Cite

Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effective for glycemic control, with many also demonstrating cardiovascular (CV) benefit, in people with type 2 diabetes (T2D). This study aimed to find a consensus on the barriers and strategies for the optimal use of GLP-1 RAs in people with T2D and high CV risk or established cardiovascular disease (CVD) in Spain. Methods: A two-round Delphi survey (53 questions) was conducted among members of four national scientific societies in Spain, including physicians experienced in the management of people with T2D. The degree of consensus was evaluated with a 7-point Likert scale, establishing consensus when ≥ 70% of the panelists agreed (6-7) or disagreed (1-2).

show abstract

Abordaje práctico de la semaglutida en el paciente con diabetes tipo 2

Escobar

Castro

Cerezo

et al. 2022

Revista Española de Cardiología Suplementos

View full text Add to dashboard Cite

Manejo de perfiles de pacientes con diabetes mellitus tipo 2 en la práctica clínica de la atención primaria en España: Programa CONTROVERTI2

Cited by 3 publications

References 20 publications

GLP-1 RAs in Spain: A Short Narrative Review of Their Use in Real Clinical Practice

GLP-1 RAs in Spain: A Short Narrative Review of Their Use in Real Clinical Practice

Barriers and Strategies to Optimize the Use of Glucagon-Like Peptide 1 Receptor Agonists in People with Type 2 Diabetes and High Cardiovascular Risk or Established Cardiovascular Disease: A Delphi Consensus in Spain

Abordaje práctico de la semaglutida en el paciente con diabetes tipo 2

Contact Info

Product

Resources

About